Sagimet Biosciences (SGMT) Enterprise Value (2023 - 2026)

Sagimet Biosciences' Enterprise Value history runs 5 years deep, the most recent figure standing at -$104.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 27.69% year-over-year to -$104.5 million; the TTM figure through Mar 2026 stood at -$104.5 million (up 27.69% YoY), while the FY2025 annual figure was -$113.1 million, up 25.21% from the prior year.
• Enterprise Value for Q1 2026 stood at -$104.5 million, up from -$113.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$18.5 million in Q2 2023, with the low at -$193.7 million in Q1 2024.
• The 5-year median for Enterprise Value is -$116.7 million (2025), against an average of -$116.6 million.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value plunged 798.92% in 2024, then rose 27.69% in 2026.
• Sagimet Biosciences' Enterprise Value stood at -$32.3 million in 2022, then slumped by 193.39% to -$94.9 million in 2023, then plunged by 59.38% to -$151.2 million in 2024, then gained by 25.21% to -$113.1 million in 2025, then increased by 7.59% to -$104.5 million in 2026.
• Business Quant data shows SGMT's Enterprise Value at -$104.5 million in Q1 2026, -$113.1 million in Q4 2025, and -$116.7 million in Q3 2025.